RNA Expression-based Analysis to Predict Response in Patients with Metastatic Mismatch Repair Proficient Colorectal Cancer Treated with Regorafenib and Nivolumab
Conclusion Xerna™ TME Panel analysis in patients with refractory metastatic pMMR CRC who were treated with regorafenib plus nivolumab might be of value for predictive clinical benefit. Further studies are needed to evaluate the predictive role of Xerna™ TME Panel analysis in patients with refractory metastatic pMMR CRC.PMID:38061339 | DOI:10.1159/000535599 (Source: Oncology)
Source: Oncology - December 7, 2023 Category: Cancer & Oncology Authors: Ruoyu Miao Dae Won Kim James Yu Mokenge Malafa Rutika Mehta Jonathan Strosberg Iman Imanirad Seema Iyer Mark Uhlik Laura Benjamin Richard Kim Source Type: research
The rate of clinically significant prostate cancer on repeat biopsy after a diagnosis of atypical small acinar proliferation: A systematic review and meta-analysis
CONCLUSION: Repeat biopsy can be safely deferred for patients diagnosed with ASAP. We believe our results may help to improve management strategies and encourage clinicians to choose more patient-friendly or non-invasive diagnostic evaluations.PMID:38061334 | DOI:10.1159/000535123 (Source: Oncology)
Source: Oncology - December 7, 2023 Category: Cancer & Oncology Authors: Wen-Tong Ji Xue-Fei Jin Yao Wang Source Type: research
RNA Expression-based Analysis to Predict Response in Patients with Metastatic Mismatch Repair Proficient Colorectal Cancer Treated with Regorafenib and Nivolumab
Conclusion Xerna™ TME Panel analysis in patients with refractory metastatic pMMR CRC who were treated with regorafenib plus nivolumab might be of value for predictive clinical benefit. Further studies are needed to evaluate the predictive role of Xerna™ TME Panel analysis in patients with refractory metastatic pMMR CRC.PMID:38061339 | DOI:10.1159/000535599 (Source: Oncology)
Source: Oncology - December 7, 2023 Category: Cancer & Oncology Authors: Ruoyu Miao Dae Won Kim James Yu Mokenge Malafa Rutika Mehta Jonathan Strosberg Iman Imanirad Seema Iyer Mark Uhlik Laura Benjamin Richard Kim Source Type: research
Clinical Impact of Early Tumour Shrinkage in Metastatic or Unresectable Oesophageal Cancer Treated with Pembrolizumab plus Chemotherapy
CONCLUSION: Our findings suggest that an ETS is a promising on-treatment marker for early prediction of further sensitivity to pembrolizumab plus CF therapy.PMID:38052183 | DOI:10.1159/000535186 (Source: Oncology)
Source: Oncology - December 5, 2023 Category: Cancer & Oncology Authors: Takahito Sugase Takashi Kanemura Tomohira Takeoka Norihiro Matsuura Yasunori Masuike Naoki Shinno Hisashi Hara Takeshi Omori Masatoshi Kitakaze Masahiko Kubo Yosuke Mukai Toshinori Sueda Shinichiro Hasegawa Hirofumi Akita Junichi Nishimura Hiroshi Wada Ma Source Type: research
Clinical Impact of Early Tumour Shrinkage in Metastatic or Unresectable Oesophageal Cancer Treated with Pembrolizumab plus Chemotherapy
CONCLUSION: Our findings suggest that an ETS is a promising on-treatment marker for early prediction of further sensitivity to pembrolizumab plus CF therapy.PMID:38052183 | DOI:10.1159/000535186 (Source: Oncology)
Source: Oncology - December 5, 2023 Category: Cancer & Oncology Authors: Takahito Sugase Takashi Kanemura Tomohira Takeoka Norihiro Matsuura Yasunori Masuike Naoki Shinno Hisashi Hara Takeshi Omori Masatoshi Kitakaze Masahiko Kubo Yosuke Mukai Toshinori Sueda Shinichiro Hasegawa Hirofumi Akita Junichi Nishimura Hiroshi Wada Ma Source Type: research
Impact of tumor shrinkage pattern with biweekly triplet gemcitabine+cisplatin+S-1 regimen for biliary tract cancers: Implications for neoadjuvant therapy from the data of KHBO1401 (KHBO1401-1A study)
CONCLUSION: GCS provided faster and greater tumor shrinkage with better survival in comparison to GC, although 20% of patients showed re-growth after 6 cycles.PMID:38048759 | DOI:10.1159/000533669 (Source: Oncology)
Source: Oncology - December 4, 2023 Category: Cancer & Oncology Authors: Shogo Kobayashi Hiroshi Wada Daisuke Sakai Hideo Baba Masashi Kanai Hirofumi Kamachi Tadatoshi Takayama Masaki Ueno Masahiro Takahashi Masayuki Sho Kenichi Yoshimura Etsuro Hatano Hiroaki Nagano Tatsuya Ioka Source Type: research
Impact of tumor shrinkage pattern with biweekly triplet gemcitabine+cisplatin+S-1 regimen for biliary tract cancers: Implications for neoadjuvant therapy from the data of KHBO1401 (KHBO1401-1A study)
CONCLUSION: GCS provided faster and greater tumor shrinkage with better survival in comparison to GC, although 20% of patients showed re-growth after 6 cycles.PMID:38048759 | DOI:10.1159/000533669 (Source: Oncology)
Source: Oncology - December 4, 2023 Category: Cancer & Oncology Authors: Shogo Kobayashi Hiroshi Wada Daisuke Sakai Hideo Baba Masashi Kanai Hirofumi Kamachi Tadatoshi Takayama Masaki Ueno Masahiro Takahashi Masayuki Sho Kenichi Yoshimura Etsuro Hatano Hiroaki Nagano Tatsuya Ioka Source Type: research
Expression of Nectin-4 in Chromophobe Renal Cell Carcinoma in a multicenter cohort - early prognostic and therapeutic considerations
CONCLUSIONS: In chRCC a small subset of tumors expresses Nectin-4 potentially amenable to Nectin-4 directed treatment. Expression of Nectin-4 is not associated with parameters of aggressiveness or survival. Due to the rare incidence of chRCC further studies with larger cohorts are warranted.PMID:38043528 | DOI:10.1159/000535473 (Source: Oncology)
Source: Oncology - December 3, 2023 Category: Cancer & Oncology Authors: Marie Mikuteit Stefanie Zsch äbitz Michael Autenrieth Wilko Weichert Arndt Hartmann Sandra Steffens Franziska Erlmeier Source Type: research
Expression of Nectin-4 in Chromophobe Renal Cell Carcinoma in a multicenter cohort - early prognostic and therapeutic considerations
CONCLUSIONS: In chRCC a small subset of tumors expresses Nectin-4 potentially amenable to Nectin-4 directed treatment. Expression of Nectin-4 is not associated with parameters of aggressiveness or survival. Due to the rare incidence of chRCC further studies with larger cohorts are warranted.PMID:38043528 | DOI:10.1159/000535473 (Source: Oncology)
Source: Oncology - December 3, 2023 Category: Cancer & Oncology Authors: Marie Mikuteit Stefanie Zsch äbitz Michael Autenrieth Wilko Weichert Arndt Hartmann Sandra Steffens Franziska Erlmeier Source Type: research
A Cohort Study of the Antitumor Efficacy and Toxicity Profile of Alpelisib for Metastatic or Locally Advanced HR+, HER2- Breast Cancer: A Single-Institution Experience
CONCLUSIONS: For progressive HR+, HER2- MBC, alpelisib + ET showed effectiveness in a real-world patient population that was comparable to published clinical trial data, regardless of starting dose. However, the effectiveness of alpelisib following previous everolimus exposure may be limited and, hence, should be a consideration to decide sequencing of therapy in these patients. Patients treated with alpelisib are at risk for clinically relevant AEs and require close monitoring.PMID:38011835 | DOI:10.1159/000534953 (Source: Oncology)
Source: Oncology - November 27, 2023 Category: Cancer & Oncology Authors: Humaira Sarfraz Shahla Bari Junmin Whiting Melissa Sur Qianxing Mo Melissa Armitage Ricardo L B Costa Source Type: research
A Cohort Study of the Antitumor Efficacy and Toxicity Profile of Alpelisib for Metastatic or Locally Advanced HR+, HER2- Breast Cancer: A Single-Institution Experience
CONCLUSIONS: For progressive HR+, HER2- MBC, alpelisib + ET showed effectiveness in a real-world patient population that was comparable to published clinical trial data, regardless of starting dose. However, the effectiveness of alpelisib following previous everolimus exposure may be limited and, hence, should be a consideration to decide sequencing of therapy in these patients. Patients treated with alpelisib are at risk for clinically relevant AEs and require close monitoring.PMID:38011835 | DOI:10.1159/000534953 (Source: Oncology)
Source: Oncology - November 27, 2023 Category: Cancer & Oncology Authors: Humaira Sarfraz Shahla Bari Junmin Whiting Melissa Sur Qianxing Mo Melissa Armitage Ricardo L B Costa Source Type: research
A Cohort Study of the Antitumor Efficacy and Toxicity Profile of Alpelisib for Metastatic or Locally Advanced HR+, HER2- Breast Cancer: A Single-Institution Experience
CONCLUSIONS: For progressive HR+, HER2- MBC, alpelisib + ET showed effectiveness in a real-world patient population that was comparable to published clinical trial data, regardless of starting dose. However, the effectiveness of alpelisib following previous everolimus exposure may be limited and, hence, should be a consideration to decide sequencing of therapy in these patients. Patients treated with alpelisib are at risk for clinically relevant AEs and require close monitoring.PMID:38011835 | DOI:10.1159/000534953 (Source: Oncology)
Source: Oncology - November 27, 2023 Category: Cancer & Oncology Authors: Humaira Sarfraz Shahla Bari Junmin Whiting Melissa Sur Qianxing Mo Melissa Armitage Ricardo L B Costa Source Type: research
A Cohort Study of the Antitumor Efficacy and Toxicity Profile of Alpelisib for Metastatic or Locally Advanced HR+, HER2- Breast Cancer: A Single-Institution Experience
CONCLUSIONS: For progressive HR+, HER2- MBC, alpelisib + ET showed effectiveness in a real-world patient population that was comparable to published clinical trial data, regardless of starting dose. However, the effectiveness of alpelisib following previous everolimus exposure may be limited and, hence, should be a consideration to decide sequencing of therapy in these patients. Patients treated with alpelisib are at risk for clinically relevant AEs and require close monitoring.PMID:38011835 | DOI:10.1159/000534953 (Source: Oncology)
Source: Oncology - November 27, 2023 Category: Cancer & Oncology Authors: Humaira Sarfraz Shahla Bari Junmin Whiting Melissa Sur Qianxing Mo Melissa Armitage Ricardo L B Costa Source Type: research
A Cohort Study of the Antitumor Efficacy and Toxicity Profile of Alpelisib for Metastatic or Locally Advanced HR+, HER2- Breast Cancer: A Single-Institution Experience
CONCLUSIONS: For progressive HR+, HER2- MBC, alpelisib + ET showed effectiveness in a real-world patient population that was comparable to published clinical trial data, regardless of starting dose. However, the effectiveness of alpelisib following previous everolimus exposure may be limited and, hence, should be a consideration to decide sequencing of therapy in these patients. Patients treated with alpelisib are at risk for clinically relevant AEs and require close monitoring.PMID:38011835 | DOI:10.1159/000534953 (Source: Oncology)
Source: Oncology - November 27, 2023 Category: Cancer & Oncology Authors: Humaira Sarfraz Shahla Bari Junmin Whiting Melissa Sur Qianxing Mo Melissa Armitage Ricardo L B Costa Source Type: research
Co-culture device for in vitro high throughput analysis of cancer associated fibroblast and cancer cell interactions
Discussion The high throughput model demonstrates that boundary condition changes can be observed between cancer cells and fibroblasts based upon the different chemotherapeutics that have been administered.PMID:38008083 | DOI:10.1159/000533773 (Source: Oncology)
Source: Oncology - November 26, 2023 Category: Cancer & Oncology Authors: Adam Germain Young-Tae Kim Source Type: research
